As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Phathom Pharmaceuticals, Inc. The largest reported stake is Frazier Life Sciences Public Fund, L.P.'s, at 7.4%. 11 filings are on record since August 13, 2025 (Schedule 13D/A, November 2, 2026).
Sell to companies like Phathom Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 5,323,356 · Sole dispositive: 0 · Shared dispositive: 5,323,356 · SCHEDULE 13D/A, 2026-11-02
- · Reporting person: BlackRock, Inc. · Sole voting: 4,293,374 · Shared voting: 0 · Sole dispositive: 4,378,647 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Reporting person: Millennium Management LLC · Sole voting: 0 · Shared voting: 3,375,834 · Sole dispositive: 0 · Shared dispositive: 3,375,834 · SCHEDULE 13G/A, 2026-07-20
- · Holder: Millennium Management LLC · Percent: 5.3% · SCHEDULE 13G
- · Holder: Millennium Management LLC · Percent: 2.7% · SCHEDULE 13G/A
Phathom Pharmaceuticals, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 7.4% | 5,323,356 | SCHEDULE 13D/A, 2026-11-02 | 2026-10-29 |
| BlackRock, Inc. | 5.5% | 4,378,647 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Carlyle Group Inc. | 4.9% | 3,496,808 | SCHEDULE 13G/A, 2025-08-28 | 2025-08-28 |
| Millennium Management LLC | 4.2% | 3,375,834 | SCHEDULE 13G/A, 2026-07-20 | 2026-06-30 |
Holding shares or following this stake? See who's behind Phathom Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Phathom Pharmaceuticals, Inc. and the records around it.
Phathom Pharmaceuticals, Inc. elsewhere on the record
Companies that share a holder
- Carlyle Group Inc. also filed stake reports on 7 other companies: SunPower Inc. (Aug 2026), Q32 Bio Inc. (Jul 2026), Medline Inc. (May 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026), Allogene Therapeutics, Inc. (Aug 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
Watch Phathom Pharmaceuticals, Inc.
Get an email when Phathom Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Phathom Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Phathom Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Phathom Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 0 | 5,323,356 | 0 | 5,323,356 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmlsp, L.P. | 0 | 5,323,356 | 0 | 5,323,356 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmlsp, L.L.C. | 0 | 5,323,356 | 0 | 5,323,356 | SCHEDULE 13D/A, 2026-11-02 |
| Frazier Life Sciences X, L.P. | 0 | 59,403 | 0 | 59,403 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls X, L.P. | 0 | 59,403 | 0 | 59,403 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls X, L.L.C. | 0 | 59,403 | 0 | 59,403 | SCHEDULE 13D/A, 2026-11-02 |
| Frazier Life Sciences XI, L.P. | 0 | 980,286 | 0 | 980,286 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls Xi, L.P. | 0 | 980,286 | 0 | 980,286 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls Xi, L.L.C. | 0 | 980,286 | 0 | 980,286 | SCHEDULE 13D/A, 2026-11-02 |
| Frazier Life Sciences IX, L.P. | 0 | 5,827,415 | 0 | 5,827,415 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls Ix, L.P. | 0 | 5,827,415 | 0 | 5,827,415 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls Ix, L.L.C. | 0 | 5,827,416 | 0 | 5,827,416 | SCHEDULE 13D/A, 2026-11-02 |
| Frazier Life Sciences XII, L.P. | 0 | 276,029 | 0 | 276,029 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls Xii, L.P. | 0 | 276,029 | 0 | 276,029 | SCHEDULE 13D/A, 2026-11-02 |
| Fhmls Xii, L.L.C. | 0 | 276,029 | 0 | 276,029 | SCHEDULE 13D/A, 2026-11-02 |
| James N. Topper | 126,508 | 5,886,819 | 126,508 | 5,886,819 | SCHEDULE 13D/A, 2026-11-02 |
| Patrick J. Heron | 14,937 | 5,886,819 | 14,937 | 5,886,819 | SCHEDULE 13D/A, 2026-11-02 |
| BlackRock, Inc. | 4,293,374 | 0 | 4,378,647 | 0 | SCHEDULE 13G, 2026-07-29 |
| Millennium Management LLC | 0 | 3,375,834 | 0 | 3,375,834 | SCHEDULE 13G/A, 2026-07-20 |
| Millennium Group Management LLC | 0 | 3,375,834 | 0 | 3,375,834 | SCHEDULE 13G/A, 2026-07-20 |
| Israel A. Englander | 0 | 3,375,834 | 0 | 3,375,834 | SCHEDULE 13G/A, 2026-07-20 |
The latest filing identifies Phathom Pharmaceuticals, Inc. by CUSIP 71722W107 and gives its principal executive office as 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK, NJ 07932 (SCHEDULE 13D/A, 2026-11-02).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2025-08-20 | Frazier Life Sciences Public Fund, L.P. | 8.6% | SCHEDULE 13D/A |
| 2025-08-25 | Millennium Management LLC | 5.9% | SCHEDULE 13G/A |
| 2025-08-28 | Carlyle Group Inc. | 4.9% | SCHEDULE 13G/A |
| 2025-11-03 | Millennium Management LLC | 7.1% | SCHEDULE 13G/A |
| 2025-11-04 | Frazier Life Sciences Public Fund, L.P. | 8.6% | SCHEDULE 13D/A |
| 2026-01-27 | Millennium Management LLC | 2.7% | SCHEDULE 13G/A |
| 2026-03-12 | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2026-07-20 | Millennium Management LLC | 4.2% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 5.5% | SCHEDULE 13G |
| 2026-11-02 | Frazier Life Sciences Public Fund, L.P. | 7.4% | SCHEDULE 13D/A |
Questions about who owns Phathom Pharmaceuticals, Inc.
Who owns Phathom Pharmaceuticals, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Phathom Pharmaceuticals, Inc.: Frazier Life Sciences Public Fund, L.P. (7.4%, Schedule 13D/A, filed 2026-11-02) and BlackRock, Inc. (5.5%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Phathom Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Phathom Pharmaceuticals, Inc. on this page are Frazier Life Sciences Public Fund, L.P. (7.4%) and BlackRock, Inc. (5.5%).
When did Frazier Life Sciences Public Fund, L.P. buy into Phathom Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Frazier Life Sciences Public Fund, L.P. on this page is the Schedule 13D/A, filed 2025-08-20, reporting 8.6%; its latest, Schedule 13D/A filed 2026-11-02, reports 7.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Phathom Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.